Direct oral anticoagulants

Direct oral anticoagulants (DOACs) are a class of orally administered prescription medications that inhibit specific targets in the coagulation cascade, most commonly factor Xa (rivaroxaban, apixaban, edoxaban) or thrombin (dabigatran). They were developed as alternatives to traditional vitamin K antagonists such as warfarin, with the aim of providing predictable anticoagulation using fixed dosing and without the need for routine laboratory monitoring in most patients. Mechanistically, factor Xa inhibitors prevent the conversion of prothrombin to thrombin, while direct thrombin inhibitors prevent thrombin-mediated fibrin formation, platelet activation, and amplification of coagulation. In healthy volunteers, these drugs show rapid oral absorption, relatively short half-lives compared with warfarin, and dose-dependent reductions in standard coagulation measures and specific anti-factor Xa or anti-IIa activity. General health applications are almost entirely in the prevention and treatment of thromboembolic disease in at-risk or diseased populations, such as atrial fibrillation, venous thromboembolism, and post‑orthopedic surgery prophylaxis, rather than in healthy individuals. Because DOACs are potent anticoagulants, their use in otherwise healthy people is limited to controlled clinical or pharmacology studies, where they serve as tools to investigate pharmacokinetics, pharmacodynamics, food effects, drug–drug interactions, and reversal strategies. These studies help define safe dose ranges, onset and offset of action, and management principles in scenarios such as overdose, bleeding, or urgent surgery.